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The chromosomal translocation t(11;14)(q13;q32) leading to cyclin-
D1 overexpression plays an essential role in the development of
mantle cell lymphoma (MCL), an aggressive tumor that remains in-
curable with current treatment strategies. Cyclin-D1 has been pos-
tulated as an effective therapeutic target, but the evaluation of this
target has been hampered by our incomplete understanding of its
oncogenic functions and by the lack of valid MCL murine models. To
address these issues, we generated a cyclin-D1–driven mouse model
in which cyclin-D1 expression can be regulated externally. These
mice developed cyclin-D1–expressing lymphomas capable of recapit-
ulating features of human MCL. We found that cyclin-D1 inactiva-
tion was not sufficient to induce lymphoma regression in vivo;
however, using a combination of in vitro and in vivo assays, we
identified a novel prosurvival cyclin-D1 function in MCL cells. Specif-
ically, we found that cyclin-D1, besides increasing cell proliferation
through deregulation of the cell cycle at the G1–S transition, seques-
trates the proapoptotic protein BAX in the cytoplasm, thereby fa-
voring BCL2’s antiapoptotic function. Accordingly, cyclin-D1 inhi-
bition sensitized the lymphoma cells to apoptosis through BAX
release. Thus, genetic or pharmacologic targeting of cyclin-D1 com-
bined with a proapoptotic BH3 mimetic synergistically killed the
cyclin-D1–expressing murine lymphomas, human MCL cell lines,
and primary lymphoma cells. Our study identifies a role of cyclin-
D1 in deregulating apoptosis in MCL cells, and highlights the poten-
tial benefit of simultaneously targeting cyclin-D1 and survival path-
ways in patients with MCL. This effective combination therapy also
might be exploited in other cyclin-D1–expressing tumors.
mouse model of MCL | ABT-737 | cyclin-D1 inhibitor drugs | targeted
therapy | oncogene addiction
Mantle cell lymphoma (MCL) is a distinct lymphoma entitythat accounts for ∼6–8% of all cases of lymphoma (1, 2).
MCL is thought to be derived from naïve pregerminal center B
lymphocytes localized in primary follicles or in the mantle region of
secondary follicles, and thus most tumors do not show somatic
hypermutation of the Ig heavy-chain coding (IGH) genes. Cyto-
logically, two major MCL subsets can be distinguished, the classical
and blastoid/pleomorphic variants, which share a characteristic
CD19+CD5+CD23− immunophenotype (2). Almost all MCL
cases show the chromosomal translocation t(11;14)(q13;q32),
which juxtaposes the CCND1 gene with IGH gene enhancers and
causes overexpression of the cyclin-D1 protein. The best-known
function ascribed to cyclin-D1 is in positive regulation of cell
cycling. In MCL cells, constitutive cyclin-D1 activation maintains
retinoblastoma (RB) protein in a phosphorylated state and
promotes cell proliferation, thus likely initiating tumorigenesis
(3). However, whether cyclin-D1 has additional oncogenic func-
tions in the lymphoma cells has not been well addressed. In B
lymphocytes, cyclin-D1 deregulation seems insufficient to induce
neoplastic transformation, given that other genetic changes are
required for the development of malignancy (3, 4). Numerous
genes have been postulated as candidates that cooperate with
cyclin-D1 to promote MCL development, including the cell-cycle
regulators P16INK4a and CDK4; the DNA-damage sensor and
repair genes ATM, TP53, and ARF; and components of the ap-
optotic machinery, such as BCL2L11 and BCL2 (3, 5–7). How-
ever, the functional mechanisms underlying the interplay of
cyclin-D1 with these oncogenic proteins and their impact on
MCL pathogenesis remain unexplored.
Clinically, there is no curative therapy for MCL; all treatment
modalities, including combined immunochemotherapy and ra-
diotherapy or intensive high-dose chemotherapy with stem cell
transplantation, have failed to prevent disease recurrence and
progression (8–10). In attempts to improve this poor outcome,
attention has turned to novel therapies targeting specific regu-
latory pathways that are essential for the growth and mainte-
nance of the transformed phenotype, some of which are
currently undergoing clinical testing (8, 10, 11). However, a rig-
orous evaluation of the molecular targets that may be suitable for
these compounds has not been conducted. Cyclin-D1, which
plays a critical role in MCL development, has emerged as one of
the most promising therapeutic targets, but its analysis has been
hampered by the lack of useful MCL mouse models (10).
To investigate the function of cyclin-D1 in MCL development
and its potential role as a therapeutic target, we generated
a cyclin-D1–driven mouse model in which cyclin-D1 expression
can be externally regulated. These mice developed lymphomas
recapitulating some features of human MCL. Our study identi-
fies a novel role for cyclin-D1 in deregulating apoptosis in MCL
cells and highlights the potential benefits of simultaneously tar-
geting cyclin-D1 and survival pathways in patients with MCL.
Results
Inhibition of Cyclin-D1 Has Moderate Effects on MCL Cell Growth but
Enhances Sensitivity to Apoptosis. Cyclin-D1 has been postulated
as a promising therapeutic target in MCL, based on its critical
role in tumor development and its overexpression in virtually all
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cases. However, inhibition of cyclin-D1 in human MCL cell lines
by siRNA resulted in a moderate effect on cell growth, leading to
accumulation of cells in G1 phase of the cell cycle and to a minor
increase in the apoptotic rates (Fig. S1A) (12). These data sug-
gest that additional genetic pathways are contributing to the
transformed phenotype in MCL cells. To identify the genes
participating in lymphomagenesis and search for valid thera-
peutic targets, we developed a combined cellular-genomic-pro-
teomics screen. In this approach, the cytotoxicity to compounds
targeting cancer-related molecular pathways was tested in MCL
cell lines and was correlated with their genomic, gene expression,
and proteomic profiles (Fig. S1B). Although the MCL cell lines
showed variable sensitivity to the drugs included in the screening
(Fig. S1C), the BH3-only mimetic ABT-737, a small molecule
that binds to BCL2, BCL-XL, and BCL-W (13), was selectively
effective in some MCL cell lines, whereas other remained re-
sistant (Fig. 1A and Fig. S1D). The reduced cell viability in the
sensitive cells after exposure to the BH3 mimetic was associated
with a marked increase in the apoptotic rates and with cleavage
of caspase 9, indicating the involvement of the intrinsic apoptotic
pathway (Fig. 1B and Fig. S1E). Similarly, ABT-737–sensitive
cells were killed by this drug in vivo after i.v. inoculation into
immunodeficient RAG2−/−γc−/− mice (lacking B, T, and den-
dritic cells) (14), whereas ABT-737–resistant MCL cells were not
(Fig. 1C). Accordingly, longer survival of mice carrying the ABT-
737–sensitive HBL2 cells was accompanied by a reduction in
lymphoma volume and attenuation of tumor glycolytic activity
(Fig. S1 F and G). We next checked whether cyclin-D1 silencing
might influence ABT-737 sensitivity. Notably, simultaneous
siRNA-mediated knockdown of cyclin-D1 and ABT-737 expo-
sure were associated with a partial reversion of tumor resistance
in ABT-737–resistant MCL cell lines (Fig. 1D and Fig. S1H).
These data suggest that inhibition of cyclin-D1 may functionally
interact with the apoptotic machinery to facilitate ABT-737–
mediated apoptosis in MCL cells.
BCL2 Genomic Amplification and Protein Expression Determine Re-
sponses to ABT-737. Analysis of the mechanisms underlying ABT-
737 sensitivity revealed that the MCL-responsive cells were dis-
tinguished by a gene expression signature composed of 93 over-
expressed genes, 13 of which (14%) mapped to chromosome
bands 18q21-q22 (hypergeometric test, P = 6.85 × 10−15), in-
cluding the BCL2 gene (Fig. 2A and Fig. S2A). Microarray-based
comparative genomic hybridization (a-CGH) and fluorescence in
situ hybridization (FISH) studies detected genomic amplification
of chromosome 18q21 including the BCL2 gene locus in the four
sensitive cell lines but not in any of the resistant tumors (Fig. 2B,
Fig. S2B, and ref. 15). In addition, BCL2 protein was expressed in
all but one of the MCL cell lines, at fivefold greater levels in those
with 18q21 amplification (Fig. 2C and Fig. S2C). However, the
expression of cyclin-D1 and of other proteins commonly altered in
MCL and/or involved in apoptosis regulation was not correlated
with ABT-737 sensitivity (Fig. 2 C and D). These data strongly
indicate that BCL2 expression levels determine the response to
ABT-737 in cyclin-D1–expressing MCL cells. To evaluate the
clinical significance of our findings, we investigated the genomic
and expression status of BCL2 in 183 primary cyclin-D1+ MCL
specimens. Twenty-seven of the 183 specimens (15%) showed
genomic gain or amplification of chromosome 18q21, including
the BCL2 gene locus (Fig. 2E and Fig. S2D). BCL2 gain/ampli-
fication was correlated with higher levels of BCL2 protein ex-
pression, as determined by Western blot analysis (Fig. 2F).
Immunohistochemistry (IHC) studies showed that almost all MCL
biopsy specimens showed expression of BCL2, ranging from very
low to high levels (Fig. 2G). Quantitative measurement of BCL2
expression assessed by IHC revealed that MCL cases with genomic
gain/amplification of the BCL2 gene had a greater number of cells
with BCL2 expression compared with nonamplified lymphomas
(mean per tumor± SEM, 13,000± 1,100 cells vs. 10,800± 540 cells;
P = 0.05, Wilcoxon signed-rank test) (Fig. S2E and Table S1).
Together, these data indicate that both cyclin-D1 and BCL2 are
coexpressed in most patients with MCL, highlighting these mole-
cules as potential targets for directed therapies.
Generation of Cyclin-D1–Expressing Lymphomas in Mice. The fore-
going results prompted us to explore the putative cyclin-D1/BCL2
interaction and their role as therapeutic targets in vivo. We gen-
erated a cyclin-D1–driven tumor model in mice in which cyclin-D1
A
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Fig. 1. Inhibition of cyclin-D1 has moderate effects on MCL
cell growth but enhances sensitivity to apoptosis. (A) ABT-737
was therapeutically effective in four MCL cell lines, whereas
six lines remained resistant (P < 0.001). (B) Treatment with
ABT-737 (250 nM) induced apoptosis in the sensitive cell lines,
as revealed by annexin V staining and cleavage of caspase 9.
Ctrl, control. (C) Kaplan–Meier overall survival (OS) curves for
immunodeficient mice transplanted with MCL cells and
treated with ABT-737 or vehicle. The ABT-737–treated mice
transplanted with ABT-737–sensitive HBL2 cells had a longer
OS than those treated with vehicle (median OS, 48 ± 2 d vs.
35 ± 3 d; P < 0.001). In contrast, mice carrying ABT-737–re-
sistant JEKO1 cells had a similar outcome in the ABT-737–
treated and control subgroups (median OS, 34 ± 2 d vs. 36 ± 1
d; P = 0.37). All experiments in mice were performed in du-
plicate with eight mice per group. (D) The combination of
cyclin-D1 silencing and ABT-737 (250 nM) exposure resulted
in a statistically significant decrease in cell viability, increase
in apoptosis, and accumulation of cells in the G1 phase in two
ABT-737–resistant MCL cell lines (Fig. S1H).
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expression could be regulated by doxycycline (Dox). For this, the
human CCND1 gene was cloned into the Combit-TA vector (16)
and stably transfected into mouse IL-3–dependent BaF3 pro-B
lymphocytes, which were selected because of their similarity to the
putative MCL cells of origin—naïve B lymphocytes with an active
VDJ recombination program (Fig. S3 A and B). In two single-cell
isolated cyclin-D1–expressing clones, CyD1-1 and CyD1-4, cyclin-
D1 expression could be silenced within 48 h after exposure to Dox
(Fig. S3C). In vitro cyclin-D1overexpression did not give these cells
the ability to grow independently of IL-3, nor did it substantially
modify cell cycle or apoptotic rates, although it did increase cell
proliferation. However, i.v. inoculation of CyD1-1 and CyD1-4
cells in RAG2−/−γc−/− mice did not induce tumor development
(Fig. S3 D and E). We next tested whether additional genetic
alterations induced by ionizing irradiation could promote trans-
formation of cyclin-D1–expressing cells (17). Irradiated CyD1-1
and CyD1-4 cells were cultured without IL-3 and injected into
immunodeficient mice. One of the CyD1-4 cell clones (obtained
after irradiation with 1 Gy and hereinafter referred to as CyD1-4–
1Gy) consistently developed tumors after 3–4 wk (medianOS, 21±
4 d) (Fig. 3A). Genomic analysis of CyD1-4–1Gy cells with a-CGH
revealed visible genomic alterations that were not present in the
original CyD1-4 cells (see below), indicating that these acquired
changes might have promoted cell transformation.
To investigate whether BCL2 overexpression could similarly
cooperate with cyclin-D1 to transform B lymphocytes, CyD1-4
cells were transfected with the human BCL2 gene cloned in the
pcDNA3.1 vector (hereinafter, CyD1-4–BCL2 cells). Injection of
2.5 × 106 cells into immunodeficient mice was associated with
tumor development starting at week 6 (median OS, 57 ± 11 d)
(Fig. 3B). Isolated cell suspensions from cyclin-D1–driven lym-
phomas grew independently of IL-3 and could be transplanted
into secondary RAG2−/−γc−/− recipients (Fig. S3F). Mouse
lymphomas consistently involved bone marrow, peripheral blood,
spleen and liver (Fig. S3G). Histopathologically, tumors were
composed of an infiltrate of large and pleomorphic cells with
a CD19+CD5−CD23−IgM− phenotype (confirmed by flow cy-
tometry analysis of cell suspensions) and with a high pro-
liferation rate, shown by Ki67 index of 100% and abundant
mitoses, thus resembling the blastoid/pleomorphic variant of
human MCL. The lymphomas showed coexpression of cyclin-D1
and BCL2 proteins. BCL2 expression was greather in CyD1-4–
BCL2 lymphomas, whereas cyclin-D1 expression was fivefold
greater in CyD1-4–1Gy1 lymphomas. P53 expression was
detected by IHC in 5–30% of the tumor cells (Fig. 3C, Fig. S3 H
and I, and Table S2). In addition, Western blot analysis identi-
fied changes typically found in blastoid MCL, such as over-
expression of CDK4, P27kip, MYC, and MCL1 proteins (Fig.
3D) (18–21). Moreover, a-CGH studies of mouse lymphomas
identified genomic alterations common to human MCL, such as
gains of mouse chromosomes 6 and 9q (syntenic with gains of
human chromosomes 3q21, 7p11-p22.3, and 15q21-q25) and
deletions of chromosome 3q (syntenic with loss of 1p21-p22) and
chromosome 19 (syntenic with the loss of human chromosome
10q21-q24, which harbors PTEN) (Fig. 3E and Fig. S3J) (7, 19).
In summary, cyclin-D1–driven lymphomas recapitulated some of
the cellular, histopathological, and genetic features of the blas-
toid/pleomorphic variants of human MCL, qualifying them as
valid experimental models for testing directed therapies in vivo.
Combined Targeting of Cyclin-D1 and BCL2 Effectively Kills Lym-
phoma Cells. Administering Dox to the cyclin-D1–expressing
lymphoma cells in culture or to the drinking water of mice led to
down-regulation of cyclin-D1 levels by >95% within 48–72 h
(Fig. 4 A and B and Fig. S4A). However, mouse lymphomas
showed moderate differences in growth rate, cell cycle, and ap-
optotic indices after Dox-induced cyclin-D1 silencing or after
exposure to ABT-737 in vitro (Fig. 4 B and C and Fig. S4B).
Remarkably, simultaneous cyclin-D1 silencing and ABT-737
exposure induced prominent proliferative arrest and apoptosis
more efficiently than cyclin-D1 inhibition or ABT-737 treatment
alone, killing the lymphoma cells synergistically (Fig. 4C and Fig.
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Fig. 2. ABT-737 sensitivity is associated with genomic amplification and overexpression of BCL2. (A) A gene expression signature based on the presence of
overexpressed genes mapped to chromosome band 18q21-q22 subclassified ABT-737–sensitive and ABT-737–resistant lymphomas. (B) Genomic amplification
of 18q21 was detected in the four ABT-sensitive MCL cell lines, but not in the resistant lymphomas (Fig. S2B). In HBL2 cells, a-CGH, cytogenetic, and FISH
analyses (Inset) revealed high-level genomic amplification of chromosome 18q21.3 caused by a tandem duplication of BCL2 along the long arm of chro-
mosome 18. (C) Western blot analysis of MCL cell lines measuring the expression of proteins involved in apoptosis regulation. (D) No association between
ABT-737 sensitivity and alterations in proteins involved in cell-cycle control, DNA damage responses, or apoptosis was observed. (E) FISH study in a lymph node
biopsy specimen from a patient with MCL (P4). Three cells had highly amplified BCL2 (green-red-yellow signals) with respect to centromeric chromosome 10
signals (blue spots) (cells marked with arrows). Two other cells had diploid karyotypes, as demonstrated by the number of green-yellow-red and blue signals
(cells marked with arrowheads). (F) Western blot analysis of BCL2 protein in primary MCL cases and in the MCL cell lines L128 and IRM2. The cases with the
highest BCL2 expression levels (P4, P5, and P7) corresponded to three cases with high-level amplification of the BCL2 gene represented in Fig. S2C. (G) IHC
analysis revealed BCL2 expression of different intensities in almost all MCL cases; it was higher in lymphomas with genomic gain/amplification of BCL2.
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S4 B and C). However, this synergy was not observed after cyclin-
D1 silencing and exposure to the BH3 mimetic TW37 (22),
bortezomib, or doxorubicin (Fig. S4D). In mice carrying cyclin-
D1–induced lymphomas, the combination of ABT-737 with Dox-
induced cyclin-D1 inhibition was associated with better respon-
ses, including a statistically significantly longer OS and clearance
of lymphoma cells detected by imaging systems compared with
control mice (Fig. 4D and Fig. S5). In vivo individual cyclin-D1
or BCL2 blocking did not modify cell morphology or pro-
liferation rate, and did not induce signs of apoptosis. In contrast,
cell proliferation and apoptotic changes were visible in the tumor
biopsy specimens with the use of the combined therapy (Fig. S6).
These data indicate that simultaneous inhibition of cyclin-D1
and BCL2 has synergistic antitumor activity on mouse lympho-
mas, recapitulating our previous results in human MCL.
Cyclin-D1 Sequestrates BAX and Inhibits ABT-737–Mediated Apoptosis.
Based on the foregoing findings, we decided to investigate the
mechanisms responsible for the enhanced therapeutic efficacy of
ABT-737 in MCL cells after cyclin-D1 inhibition. Consistent with
its role in cell-cycle regulation, a decrease in cyclin-D1 led to de-
creased phosphorylation of RB and increased P27kip expression in
mouse lymphomas (Fig. S7A). However, no apparent changes
were observed in the expression levels of the apoptotic modulators
Bcl2, Mcl1, Bcl-xl, Bax, and Bak, among others (Fig. S7B). No-
tably, using flow cytometry, we found that the unbound fraction
(active conformation) of BAX, a protein that functions as a final
effector of the apoptotic cascades, was increased after cyclin-D1
silencing in the mouse lymphomas and in ABT-737–resistant MCL
cell lines (Fig. 5A). Further analysis demonstrated that cyclin-D1
can complex with BAX in the cytoplasm of the lymphoma cells.
Using immunofluorescence (IF) studies coupled with Western blot
analysis of nuclear/cytoplasmic cellular protein fractions, we ob-
served that most cyclin-D1 protein was present in the cytoplasm of
both human and murine lymphomas, whereby it colocalized with
BAX (Fig. 5 B and C). Accordingly, in the human MCL cell line
JEKO1, the presence of BAX (but not of BAK) was detected by
immunoblotting after cyclin-D1 immunoprecipitation. Likewise, in
the cyclin-D1–expressing lymphomas, cyclin-D1 formed complexes
with Bax, but not with Bak, Puma, Noxa, Bim, or Bad (Fig. 5D and
Fig. S7C). As control for the experiment, the immunoprecipitation
of a known partner of cyclin-D1, CDK4, was included (Fig. S7D).
Silencing of Bax with siRNA in the lymphoma cells abrogated the
therapeutic synergy between cyclin-D1 inhibition and ABT-737,
indicating a prominent role of Bax in the resistance to the BH3
mimetic (Fig. S7E). These results reveal a mechanism in which the
proapoptotic BAX protein is sequestrated by overexpressed cyclin-
D1 in the cytoplasm of the lymphoma cells, thereby impeding
apoptosis after ABT-737 exposure. After therapeutic depletion of
cyclin-D1, BAX protein is released, exposing lymphoma cells to
the ABT-737 action and facilitating apoptosis.
Pharmacologic Inhibition of Cyclin-D1 and BCL2 Is an Effective
Combination for Treating Human MCL. Our experimental data sug-
gest that therapy with ABT-737 could be selectively active in
a fraction of MCL cases with increased BCL2 expression (∼15%
of patients with MCL, according to Fig. 2 E–G and Fig. S2 D and
E), but that with simultaneous cyclin-D1 silencing, the BH3 mi-
metic might be clinically effective in most patients with MCL
irrespective of BCL2 expression. To begin to translate these
findings to the clinical setting, we tested the therapeutic activity of
the cyclin-D1/CDK inhibitor seliciclib (roscovitine), alone and in
combination with ABT-737, in the human MCL cell lines and in
the cyclin-D1–expressing mouse lymphomas (23). Roscovitine
inhibited cyclin-D1 expression in all tested MCL cell lines and
mouse lymphomas in a dose-dependent manner, increasing the
unbound BAX protein fractions from 16% to 33% (Fig. 5 E and
F). Thus, in the MCL cell lines as well as in the mouse lympho-
mas, the combination of roscovitine and ABT-737 resulted in
decreased cell survival and massive apoptosis (Fig. 5G and Table
S3). However, MCL cell lines represent advanced models of
disease with therapeutic responses that might not be extrapolated
to patient lymphomas. Therefore, fresh peripheral blood mono-
nuclear cells were isolated from four unselected patients di-
agnosed with cyclin-D1+ MCL with leukemic disease and
incubated with roscovitine and ABT-737. Responses to ABT-737
were correlated with BCL2 expression levels in three of the four
cases. Nevertheless, the combination therapy of ABT-737 and
roscovitine induced marked growth retardation and massive ap-
optosis in all cases irrespective of BCL2 expression, with
responses comparable to those observed in the human MCL cell
lines (Fig. 5H). Taken together, these data demonstrate that
concomitant roscovitine and ABT-737 exposure is therapeutically
effective in human MCL cell lines and in primary MCL cells. Our
results highlight the potential benefit of simultaneously targeting
cyclin-D1 and survival pathways for the effective treatment of
most cases of human MCL, in agreement with the observations in
the mouse lymphoma model. On the basis of these findings, we
think that the synergistic combination of roscovitine and ABT-737
should be tested in a clinical trial with patients with MCL.
Discussion
Here we have defined a role of cyclin-D1 in deregulating apo-
ptosis by interacting with BAX in the cytoplasm of MCL cells
that may have therapeutic implications. A key element in our
work is the murine lymphoma model generated by adding sec-
ondary changes to cyclin-D1–expressing B lymphocytes that were
engrafted in immunocompromised mice. Silencing of cyclin-D1
in these mice showed that cyclin-D1 inhibition did not kill the
lymphoma cells, but did sensitize them to apoptosis. Our data
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Fig. 3. Characterization of cyclin-D1–expressing lymphomas in mice. (A) In-
jection of CyD1-4–1Gy cells in mice was associated with consistent de-
velopment of tumors after 3–4 wk (nine mice per group). (B) CyD1-4–BCL2 cells
did not grow independent of IL-3 in vitro, but induced tumor development in
immunodeficient mice starting at week 6 (nine mice per group). (C) Histo-
pathological and IHC studies of CyD1-4–1Gy and CyD1-4–BCL2 lymphomas
revealed similar profiles to those of the pleomorphic variant of human MCL.
HE, H&E staining. (D) Western blot analysis of mouse lymphomas identified
common changes that are characteristic of human blastoid/pleomorphic MCL
variants, such as overexpression of CDK4, P27kip, MYC, and MCL1 proteins. (E)
Example of whole-genome a-CGH analysis of a mouse lymphoma, showing
genomic alterations that overlap with those observed in the blastoid/pleo-
morphic variants of human MCL, such as the gains of human chromosomes 3q
and 7p. In addition, other genomic changes that are characteristic of MCL
cells, such as the loss of chromosome 1p21-p22, were identified.
12464 | www.pnas.org/cgi/doi/10.1073/pnas.1018941108 Beltran et al.
indicate the potential benefit of simultaneously targeting cyclin-
D1 and survival pathways in patients with MCL.
The role of different oncogenes in initiating and maintaining
cancer has previously been investigated in conditional transgenic
mouse models. Remarkably, inactivation of some oncogenes was
sufficient to revoke tumors, including BCR-ABL–induced leu-
kemias, MYC-induced lymphomas and carcinomas, and lung
carcinomas and melanomas after KRAS and HRAS inactivation
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Fig. 4. Synergistic cooperation of cyclin-D1 and BCL2 to kill MCL in vivo. (A and B) Administration of Dox to mouse lymphoma cells in culture (4 μg/mL) and to
the drinking water of mice led to cyclin-D1 silencing (>95%) within 48–72 h, as measured by qRT-PCR, Western blot analysis, and IHC analysis. (B) Liver biopsy
specimens in mice treated and not treated with Dox are shown. HE, H&E staining. (C) Dox-induced cyclin-D1 inhibition or treatment with ABT-737 (250 nM) of
mouse lymphomas was associated with moderate changes in growth and apoptotic rates. Notably, the simultaneous cyclin-D1 silencing and ABT-737
treatment had a synergistic therapeutic effect. NT, no treatment. (D) Mice engrafted with CyD1-4–1Gy or CyD1-4–BCL2 lymphomas received Dox, ABT-737,
Dox plus ABT-737, or vehicle. Simultaneous therapeutic targeting of cyclin-D1 and BCL2 was associated with a statistically significantly longer OS in engrafted
mice compared with the group of mice treated with vehicle, Dox, or ABT-737 (median OS, 38 ± 4 d vs. 32 ± 3 d for CyD1-4–1Gy lymphomas, P < 0.05; and 20 ±
2 d vs. 17 ± 1 d for CyD1-4–BCL2 lymphomas, P < 0.001). All experiments in mice were performed in duplicate, with eight mice per group.
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Fig. 5. Inhibition of cyclin-D1 enhances apoptotic responses to ABT-737 therapy by modifying BAX conformational activation in MCL. (A) Flow cytometry
revealed an increase in the unbound BAX protein fraction after cyclin-D1 silencing in CyD1-4–1Gy and CyD1-4–BCL2 lymphomas (31% ± 2% vs. 2% ± 2% and
19% ± 0.6% vs. 3% ± 0.5%; P < 0.001) and in the ABT-resistant JEKO1 cell line (4% ± 2% vs. 0.8% ± 0.2%; P < 0.05). Increments in the unbound fraction of
BAX after cyclin-D1 silencing are shown. (B) IF analysis of cyclin-D1 (green) and BAX (red) in human MCL and murine lymphomas show that both proteins are
detected in the cytoplasm, where they colocalize. Nuclei are contrasted with DAPI (blue). (C) Western blot analysis of cyclin-D1 and BAX in the cytoplasmic
and nuclear cellular fractions of the human and murine lymphoma cells revealed that cyclin-D1 is preferentially present in the cytoplasm and only a small
portion is observed in the nuclei, whereas BAX is a cytoplasmic protein. Lamin A/C and β-tubulin were used as controls of nuclear and cytoplasmic cellular
fractions, respectively. (D) Immunoprecipitation of cyclin-D1 complexes shows the presence of BAX in JEKO1 cells and in CyD1-4–1Gy and CyD1-4–BCL2
lymphomas. (E) Roscovitine (Rosc) inhibited cyclin-D1 expression in human MCL cell lines and in mouse lymphomas in a dose-dependent manner. (F)
Roscovitine (20–40 μM) increased the unbound BAX protein fraction in the MCL cell lines JEKO1 (24 ± 0.7% vs. 0.7 ± 0.09%; P < 0.001) and REC1 (23 ± 0.1% vs.
4.7 ± 0.01%; P < 0.01), and in CyD1-4–1Gy and CyD1-4–BCL2 mouse lymphomas (34 ± 2.9% vs. 1.22 ± 0.31% and 17 ± 0.01% vs. 0.8 ± 0.1%; P < 0.05).
Increments in the unbound fraction of BAX after roscovitine exposure are shown. (G) Roscovitine (30 μM) had a synergistic therapeutic effect in combination
with ABT-737 (250 nM) in the treatment of MCL-resistant cell lines and of CyD1-4–1Gy and CyD1-4–BCL2 mouse lymphomas. (H) Isolated mononuclear cells
from four patients with MCL with leukemia disease were treated in vitro with roscovitine (10 μM) plus ABT-737 or ABT-737 alone. The global OS curve for the
four patients after the different treatments is shown. (Inset) Western blot analysis for cyclin-D1 and BCL2 proteins.
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(24). This concept has been termed “oncogene addiction.”
However, in our mouse model, cyclin-D1 inhibition was not as-
sociated with lymphoma regression in vivo, indicating that this
protein is not essential for MCL maintenance. This finding was
not totally unexpected, given that the development of MCL
differs from that of cancers driven by potent oncogenes. Thus,
human MCL is thought to be generated by a multistep process
initiated by CCND1/cyclin-D1 activation and followed by se-
lected genetic changes that are necessary for tumor development
(3). Indeed, our results are comparable with those from other
mouse models that did not experience tumor regression after
inactivation of the primary oncogene due to the presence of
specific secondary genetic changes (16, 24). We speculate that in
MCL cells, cyclin-D1 behaves as a weak oncogenic factor that is
unable to induce malignancy directly, requiring other cooperat-
ing genetic hits to produce transformation. Likewise, single in-
activation of cyclin-D1 is not sufficient to ensure tumor regression,
but does unlock selected cooperating oncogenic pathways that
may be used for therapeutic intervention. Accordingly, a potent
therapeutic effect was observed after silencing cyclin-D1 and
targeting the apoptotic machinery, which killed human and
mouse lymphomas synergistically. These data suggest that cyclin-
D1 may represent the “Achilles’ heel” in MCL cells that needs to
be targeted to eventually cure the disease.
The mechanism underlying this effective therapeutic synergy may
rely on the interaction of the overexpressed cyclin-D1 with the
proapoptotic protein BAX, which was partially sequestrated in the
cytoplasm of the lymphoma cells and functionally inactivated. Ac-
cordingly, therapeutic depletion of cyclin-D1 using siRNA or
pharmacologic inhibitors released BAX protein, thereby facilitating
ABT-737–mediated apoptosis. Our data indicate that along with
deregulating the cell cycle, cyclin-D1 plays a role in modulating the
apoptotic pathways in MCL cells. However, whether cyclin-D1 can
also bind to BAX in other malignancies that commonly show cyclin-
D1 expression, such as multiple myeloma or breast cancer, is cur-
rently not known. Nevertheless, the direct interaction of cyclin-D1
with BAX has previously been reported in human skin keratino-
cytes (25). In this line, cyclin-D1 has been shown to mediate apo-
ptosis in B lymphocytes through modulation of molecular
chaperones (26). Based on the putative interaction of cyclin-D1
with multiple proteins in the lymphoma cells and on its recently
demonstrated role as a transcriptional regulator (27), we cannot
discount the possibility that other factors participating in diverse
molecular pathways are modified after cyclin-D1 inactivation. If so,
then additional therapeutic synergies between anti–cyclin-D1 ther-
apies and other compounds may exist, and these could be exploited
to treat patients with MCL. In summary, our results provide a ra-
tional framework for the clinical evaluation of the combination of
cyclin-D1/CDK inhibitors, such as roscovitine and ABT-737, in
patients with MCL, a disease that urgently needs a curative therapy.
Materials and Methods
Human Cell Lines and Patient Samples. Ten human-derived MCL cell lines and
biopsy specimens from 183 patients diagnosed with MCL were studied. In
addition, mononuclear cells isolated from fresh peripheral blood of four
patients with leukemic MCL were used in the in vitro therapeutic experi-
ments. All clinical samples were obtained before initiation of therapy. Human
investigations were performed after approval by the Institutional Review
Board on Scientific and Ethical Affairs.
Generation of Human Xenografts in Mice and of the Cyclin-D1–Driven Mouse
Lymphoma Models Mouse experiments were performed in the Center for
Applied Medical Research’s animal core facilities after approval by the local
Animal Ethics Committee. Mouse xenografts were generated and monitored
as reported previously (28). To generate the cyclin-D1–expressing lymphoma
model, a 1.1-kb fragment of human CCND1 cDNA was amplified by PCR,
digested with EcoRV, and ligated to the vector Combit-TA at the ScaI site (16).
Detailed descriptions of mouse generation and all experimental proce-
dures are provided in SI Materials and Methods.
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